JWH-018 (1-pentyl-3-(1-naphthoyl)indole)

Cannabinoidsmoked · inferred

Prototypical synthetic cannabinoid (Spice/K2), representative of the entire synthetic cannabinoid receptor agonist (SCRA) class. Full CB1 and CB2 agonist (4-5x higher affinity than THC, full agonist vs. THC's partial agonism). This full agonism at CB1 explains the severe toxicity — seizures, psychosis, hyperthermia, rhabdomyolysis, acute kidney injury, and death — that distinguishes SCRAs from natural cannabis. Extensive CYP metabolism to multiple active metabolites. >99% protein bound. Mass casualty events (e.g., New York "zombie" outbreak 2016) have occurred from batches spiked with SCRAs. Unpredictable potency and toxicity make these among the most dangerous recreational drugs.

Projected serum levels — 1 mg, as needed (shown daily)

JWH-018 (1-pentyl-3-(1-naphthoyl)indole)
JWH-018 (1-pentyl-3-(1-naphthoyl)indole) modeled serum levels, 1 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 mg as needed (shown daily) (smoked).

Modeled steady state after ~1 days: peak ≈ 0.41 mg, trough ≈ 0.001 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Cannabinoid
Route modeled
Smoked
Model confidence
inferred
Half-life
2.5 h
Common dose
1 mg
Suggested maximum
3 mg/day
Reference dose range
0.50–3 mg (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • danger
    Efavirenz (Sustiva) + JWH-018 (1-pentyl-3-(1-naphthoyl)indole) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change JWH-018 (1-pentyl-3-(1-naphthoyl)indole) AUC by ~0.38x

  • danger
    Levothyroxine (Synthroid) + JWH-018 (1-pentyl-3-(1-naphthoyl)indole) Protein binding

    JWH-018 (1-pentyl-3-(1-naphthoyl)indole) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic…

  • danger
    Rifampin + JWH-018 (1-pentyl-3-(1-naphthoyl)indole) CYP induction

    Rifampin inducer of CYP3A4 predicted to change JWH-018 (1-pentyl-3-(1-naphthoyl)indole) AUC by ~0.38x

  • danger
    Tacrolimus (Prograf) + JWH-018 (1-pentyl-3-(1-naphthoyl)indole) Protein binding

    JWH-018 (1-pentyl-3-(1-naphthoyl)indole) may displace Tacrolimus (Prograf) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index;…

  • danger
    Warfarin (Coumadin) + JWH-018 (1-pentyl-3-(1-naphthoyl)indole) Protein binding

    JWH-018 (1-pentyl-3-(1-naphthoyl)indole) may displace Warfarin (Coumadin) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index;…

  • warning
    Apigenin + JWH-018 (1-pentyl-3-(1-naphthoyl)indole) Protein binding

    Apigenin may displace JWH-018 (1-pentyl-3-(1-naphthoyl)indole) from plasma protein binding sites, transiently raising free drug concentration.

Serum checks 225 modeled interaction pairings for jwh-018 (1-pentyl-3-(1-naphthoyl)indole) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Synthetic cannabinoid receptor agonists — a review of the clinical pharmacology and toxicology Tait RJ et al. · The Lancet Psychiatry, 2016 DOI

    Comprehensive clinical review documenting the pharmacology of SCRAs including JWH-018 as the prototypical compound, their full CB1/CB2 agonism (vs THC partial agonism) as the mechanism of severe toxicity, and the range…

  2. Notes from the Field: "Zombie" Outbreak Caused by Synthetic Cannabinoid — New York, 2016 Adams AJ et al. · MMWR Morbidity and Mortality Weekly Report, 2017 DOI

    CDC report documenting a mass casualty event in Brooklyn, New York, where 33 people were hospitalized after consuming synthetic cannabinoid-spiked material, exhibiting "zombie-like" behavior (severe CNS depression…

2 published studies referenced in the app, each with a plain-language summary.